ArticleDermatology and therapy2026
A Retrospective Real-World Comparison of Topical Delgocitinib and Localized Cream Psoralen-Ultraviolet A in Chronic Hand Eczema.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and Safety of Delgocitinib and Its Impact on Patient's Perspective for Moderate-to-severe Chronic Hand Eczema in Adults: A 16-week Real-world Prospective Multicentre Study.Acta dermato-venereologica · 2026Observational
- D-CARE (Delgocitinib-Chronic hAnd Eczema Response Evaluation): A Retrospective, Multicenter, Real-World Study of Patients with Chronic Hand Eczema (CHE) Treated with Delgocitinib 2% Cream-Temporal Analysis of Symptom and Clinical Sign Response.Dermatology and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic hand eczema (CHE) remains difficult to treat, particularly in patients unresponsive or intolerant to topical corticosteroids. Although topical delgocitinib, the first topical JAK inhibitor approved for CHE, provides a steroid-free alternative, comparative real-world data versus localized cream psoralen-ultraviolet A (PUVA) are missing. This retrospective real-world study compared the short-term effectiveness and patient-reported outcomes of topical delgocitinib and localized cream PUVA in patients with CHE under routine-care conditions.
methodsThis retrospective cohort study analyzed anonymized routine-care data of patients with moderate-to-severe CHE treated between 2024 and 2025 at a tertiary center. Patients received topical delgocitinib twice daily or localized cream PUVA with as-needed topical corticosteroids (TCS). Twenty-two patients per group completed 12 weeks of delgocitinib or 20-25 PUVA sessions plus TCS (per-protocol). Disease severity (Physician's Global Assessment, PGA), quality of life (Dermatology Life Quality Index, DLQI), and symptom numerical rating scales (pruritus, pain, sleep disturbance) were assessed at baseline and treatment end.
resultsBoth therapies significantly improved all endpoints (p < 0.001). Median DLQI improvement was 10 with delgocitinib versus 7.5 with PUVA (p = 0.15). PGA 0/1 responses were 82% vs 73% (p = 0.72). DLQI improvement ≥ 4 points occurred in 91% vs 77% (p = 0.41). Relapses were more frequent after PUVA. Two delgocitinib non-responders improved with alitretinoin. Most delgocitinib responders continued proactive low-frequency use to maintain remission; one remained clear 3 months after stopping treatment.
conclusionDelgocitinib and PUVA provided comparable short-term clinical efficacy in CHE, with a numerically greater DLQI reduction for delgocitinib. Proactive delgocitinib maintenance may help sustain disease control. Subtype-adapted treatment strategies could further optimize outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.